Medicare Enrolled
Dr. Muhamad Alhaj Moustafa, M.D.
Hematology & Oncology · Jacksonville, FL
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Alhaj Moustafa from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Alhaj Moustafa?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Alhaj Moustafa
Dr. Muhamad Alhaj Moustafa is a hematology & oncology specialist in Jacksonville, FL, with 11 years of NPI registration. Based on federal Medicare data, Dr. Alhaj Moustafa performed 83,601 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Dr. Alhaj Moustafa received a total of $13,942 from 28 pharmaceutical and/or device companies across 77 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Alhaj Moustafa is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 11 years of NPI registration
▲ Top 9% volume in FL
$13,942 industry payments
Florida License Status
FL DOH · MQA1
Active license
None
Board action on record
0
Recent admin complaints
| Profession | License # | Status | Expires | Board Action |
|---|---|---|---|---|
| Medical Doctor | 135023 | Clear | January 31, 2028 | — |
Data from Florida Department of Health Medical Quality Assurance.
License records are public under Chapter 119, Florida Statutes.
Verify directly on FL DOH →
Medicare Practice Summary — 2023
Medicare Utilization ↗83,601
Medicare services
Top 9% in FL for hematology & oncology
Not available
Unique patients (not deduplicated)
$16
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Pembrolizumab injection (Keytruda) | 13,202 | $39 | $187 |
| Filgrastim injection (Nivestym) for white blood cells An injection of the biosimilar medication filgrastim-aafi (Nivestym) at a dose of 1 microgram. |
10,800 | $0 | $1 |
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
9,150 | $0 | $1 |
| Nivolumab injection (Opdivo) | 8,960 | $21 | $102 |
| Daratumumab injection (Darzalex) An injection containing daratumumab and hyaluronidase-fihj administered under the skin. |
5,760 | $38 | $190 |
| Iron infusion (Feraheme) An injection of ferumoxytol used to treat iron deficiency anemia in patients not on dialysis. |
5,610 | $0 | $2 |
| Paclitaxel chemotherapy injection | 4,836 | $0 | $2 |
| Darbepoetin injection (Aranesp) for anemia An injection of darbepoetin alfa used for non-end-stage renal disease purposes. |
4,070 | $2 | $11 |
| Denosumab injection (Prolia/Xgeva) | 2,700 | $19 | $91 |
| Paclitaxel protein-bound particle injection An injection of paclitaxel formulated as protein-bound particles. This code specifies the administration of the medication measured in milligrams. |
2,600 | $10 | $51 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,888 | $0 | $4 |
| Carfilzomib injection, 1 mg This code represents the administration of a 1 mg dose of carfilzomib via injection. |
1,700 | $36 | $174 |
| Immune globulin infusion (Gammagard) An injection of immune globulin (Gammagard Liquid) to provide antibodies. The dose specified is 500 mg. |
1,550 | $34 | $138 |
| Bevacizumab-bvzr biosimilar injection, 10 mg An injection of bevacizumab-bvzr, a biosimilar medication, administered in a 10 mg dose. |
1,510 | $21 | $182 |
| Anti-nausea injection (ondansetron/Zofran) | 1,500 | $0 | $5 |
| Rituximab-pvvr biosimilar injection, 10 mg An injection of rituximab-pvvr, a biosimilar medication, administered in a 10 mg dose. |
1,480 | $23 | $194 |
| Injection, atropine sulfate, 0.01 mg | 745 | $0 | $1 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
527 | $12 | $216 |
| Bortezomib injection, 0.1 mg Administration of a 0.1 mg dose of bortezomib medication via injection. |
525 | $4 | $9 |
| Anti-nausea injection (Aloxi/palonosetron) | 440 | $1 | $8 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
340 | $98 | $869 |
| Injection, irinotecan, 20 mg | 257 | $2 | $24 |
| Carboplatin chemotherapy injection, 50 mg Administration of a 50 mg dose of carboplatin, a chemotherapy medication, via injection. |
252 | $2 | $30 |
| Pegfilgrastim-jmdb injection An injection of pegfilgrastim-jmdb, a biosimilar medication. The dose specified is 0.5 mg. |
252 | $91 | $454 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 188 | $3 | $34 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
185 | $90 | $450 |
| Blood sample collection from implanted device This procedure involves drawing a blood sample directly from a medical device that has been surgically placed in the body. |
176 | $19 | $135 |
| Fluorouracil injection, 500 mg Administration of a 500 mg dose of fluorouracil medication via injection. |
168 | $2 | $31 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
131 | $2 | $82 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
125 | $11 | $102 |
| Magnesium sulfate injection, per 500 mg An injection of magnesium sulfate administered in 500 mg increments. |
120 | $1 | $19 |
| Injection, leucovorin calcium, per 50 mg | 118 | $3 | $23 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
115 | $10 | $114 |
| Cyclophosphamide, 100 mg | 115 | $16 | $118 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 106 | $133 | $492 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
104 | $137 | $604 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
101 | $22 | $212 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
100 | $22 | $233 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
99 | $48 | $446 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
93 | $96 | $452 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
92 | $1 | $38 |
| Cisplatin chemotherapy injection, 10 mg Administration of a 10 mg dose of cisplatin, a chemotherapy medication, via injection. |
91 | $2 | $35 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
74 | $47 | $426 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
70 | $55 | $352 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
64 | $16 | $154 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
61 | $25 | $345 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
61 | $26 | $200 |
| Prolonged office E/M service, first 15 minutes This code is used for additional time spent by a physician beyond the maximum required time of a primary office or outpatient evaluation and management service. It is billed in 15-minute increments based on total time spent on the date of the primary service. |
61 | $26 | $123 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
57 | $7 | $47 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
55 | $64 | $314 |
| Normal saline infusion, 500 ml Administration of sterile normal saline solution through an intravenous line. This procedure involves the infusion of a 500 ml unit of the solution. |
51 | $1 | $79 |
| New patient office visit, complex (60-74 min) | 39 | $159 | $891 |
| Concurrent intravenous infusion Administration of medication or fluid into a vein for therapy, prevention, or diagnosis while another infusion is being given. |
30 | $15 | $143 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
26 | $43 | $370 |
| IV chemotherapy initiation with community continuation Initiation of an intravenous chemotherapy infusion in a clinic using clinic supplies, with continuation of the infusion in a community setting such as home or assisted living. |
24 | $133 | $993 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
19 | $140 | $877 |
| Hospital discharge management, 30+ min This service covers the care provided by a physician or qualified healthcare professional on the day a patient is discharged from the hospital. It requires more than 30 minutes of total time spent on the day of discharge. |
15 | $92 | $487 |
| Intravenous drug injection A procedure involving the administration of a medication or substance directly into a vein. |
13 | $29 | $600 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
9.7% high complexity
89.0% medium
1.3% routine
Industry Payment Transparency
Open Payments through 2024 ↗$13,942
Total received (2018-2024)
Avg $1,992/year across 7 years
Top 32% in FL for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
28
Companies
77
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →
Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$4,449
2023
$1,139
2022
$827
2021
$453
2020
$2,745
2019
$3,692
2018
$637
Payments by company (2024)
Genentech USA, Inc.
$2,702
BeiGene USA, Inc.
$675
AstraZeneca Pharmaceuticals LP
$525
PFIZER INC.
$209
Genentech, Inc.
$137
E.R. Squibb & Sons, L.L.C.
$121
Kyowa Kirin, Inc.
$79
Top 3 companies account for 87.7% of 2024 payments
All-time payments by company (2018-2024) ›
Aurobindo Pharma USA, Inc.
$4,996
Genentech USA, Inc.
$2,981
AbbVie Inc.
$692
BeiGene USA, Inc.
$675
AstraZeneca Pharmaceuticals LP
$525
CSL Behring
$500
Kyowa Kirin, Inc.
$456
Amgen Inc.
$432
Seagen Inc.
$383
Lilly USA, LLC
$345
Alexion Pharmaceuticals, Inc.
$268
PFIZER INC.
$209
Janssen Biotech, Inc.
$179
Seattle Genetics, Inc.
$178
Genentech, Inc.
$137
Daiichi Sankyo Inc.
$130
Janssen Scientific Affairs, LLC
$123
Eli Lilly and Company
$122
E.R. Squibb & Sons, L.L.C.
$121
Kite Pharma, Inc.
$112
Agios Pharmaceuticals, Inc.
$106
Epizyme, Inc.
$87
Eisai Inc.
$55
Celgene Corporation
$49
Puma Biotechnology, Inc.
$23
Astellas Pharma Global Development
$23
Jazz Pharmaceuticals Inc.
$18
Lexicon Pharmaceuticals, Inc.
$17
Top 3 companies account for 62.2% of all-time payments
Associated products mentioned in payments ›
ABECMA · ADCETRIS · ALIMTA · BRUKINSA · CALQUENCE · CYRAMZA · Columvi · DARZALEX · ELREXFIO · Herceptin · IMBRUVICA · INJECTAFER · Kyprolis · Lenvima · Lunsumio · NERLYNX · POLIVY · POTELIGEO · Polivy · Poteligeo · Revlimid · SOLIRIS · TIBSOVO · Tazverik · VENCLEXTA · VERZENIO · VYXEOS · XOSPATA · Xermelo · ZYTIGA · Zevalin
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Geographic Context
Hematology & oncology specialists in nearby ZIP areas
104
County median income
$68,447
Nearest hospital to ZIP centroid (approximate)
MAYO CLINIC
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | ✓ PECOS | PECOS snapshot |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Alhaj Moustafa is a mixed practice specialist, with above-average Medicare volume (top 9% in FL).
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Alhaj Moustafa experienced with pembrolizumab injection (keytruda)?
Based on Medicare claims data, Dr. Alhaj Moustafa performed 13,202 pembrolizumab injection (keytruda) services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Alhaj Moustafa receive payments from pharmaceutical companies?
Yes. Dr. Alhaj Moustafa received a total of $13,942 from 28 companies across 77 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Alhaj Moustafa's costs compare to other hematology & oncology specialists in Jacksonville?
Dr. Alhaj Moustafa's average Medicare payment per service is $16. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Alhaj Moustafa) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Jacksonville
Browse hematology & oncology specialists in Jacksonville ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in FL
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in FL
Which FL hematology & oncology specialists receive the most from drug and device companies.
By company
Aurobindo Pharma USA, Inc. Payments to Doctors
See all physicians who received payments from Aurobindo Pharma USA, Inc.
By company
Genentech USA, Inc. Payments to Doctors
See all physicians who received payments from Genentech USA, Inc.
By company
AbbVie Inc. Payments to Doctors
See all physicians who received payments from AbbVie Inc.
About this page
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology